Although BI in the earlier stages of drug development remains an emergent solution area in the pharmaceutical market, contextual forces such as pipeline productivity pressures and growing generic competition will drive increased spending on BI in the near future.
Scope of this title: Identifies potential growth areas for technology in Big Pharma in Europe Quantifies spending on BI solutions by pharmaceutical end-user segments Segments IT spending by technology, country and end-user group
Highlights of this title: The adoption of BI solutions will exhibit strong growth over the next five years. The Biotech segment will increase their spending on BI solutions more quickly than Big Pharma BI adoption by clinical end-user groups will demonstrate the most rapid growth compared to R&D, manufacturing and sales & marketing groups.
Reasons to order your copy: Understand the potential opportunity size for BI solutions in the pharmaceutical market. Identify the BI technology areas in which pharmaceutical companies will invest the most heavily. Recognize the differences in BI spending across segments of the market and end-user groups.
